Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications. Its lead candidate, EDP-1815, is being evaluated in inflammatory disorders including psoriasis and atopic dermatitis, with data suggesting potential for broad anti-inflammatory activity. Evelo is also advancing oncology programs in collaboration with strategic partners, exploring how gut-based immunomodulation can enhance the body’s natural defenses against tumors. Across its portfolio, Evelo seeks to demonstrate safety and efficacy in large patient populations through controlled, placebo-led studies.
Founded in 2016 and headquartered in Cambridge, Massachusetts, Evelo Biosciences has built a multidisciplinary team with expertise in immunology, microbiology and clinical development. The company operates research facilities in the United States and maintains collaborations with leading academic institutions and biopharmaceutical organizations to support its discovery and translational efforts. Evelo’s mission is to pioneer a novel class of orally administered therapies that address unmet needs in immune-mediated diseases.
Evelo’s leadership team combines experience from both emerging biotech ventures and established pharmaceutical companies, guiding the progression of its oral biologic candidates through regulatory milestones. With a focus on scalable, patient-friendly formulations, Evelo aims to expand access to next-generation immunotherapies and deliver meaningful advances in the treatment of chronic inflammatory disorders and cancer.
AI Generated. May Contain Errors.
Free EVLO Stock Alerts